Abstract
1. Pirenperone, an antagonist of the serotonin2-receptors, in contrast to haloperidol, is a selective antagonist of apomorphine aggressiveness. Prolonged joint administration of definite doses of naloxone with apomorphine induces various subtypes of serotonin2-receptors, which is expressed in an inhibition of head shakings and the appearance of spontaneous aggressiveness after the administration of quipazine, a stimulator of serotonin2-receptors. 2. Cholecystokinin tetrapeptide significantly enhances the electrical pain aggressiveness and, in the same doses, decreases the number of head shakings induced by quipazine. Pirenperone is a selective blocker of the action of cholecystokinin tetrapeptide. 3. Cholecystokinin tetrapeptide may be an endogenous modulator of the sensitivity of the serotonin receptors. It is suggested that its functional role consists of activation of the serotonin2-receptors that turn on the defensive aggressive reactions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
